Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market IntelliSpace Portal 9.0 and a range of innovative applications for Radiology in the U.S. The latest release of Philips’ clinical informatics platform for advanced visual analysis and quantification of medical images now offers enhanced additional applications for Longitudinal Brain Imaging and Multi-Modality Tumor Tracking, as well as optimized Lung Nodule Assessment.
IntelliSpace Portal 9.0 has been available outside of the U.S. since November 2016 and will be available in the world’s largest healthcare market as of this month.